
Ya-Chi Chen, Pharm.D.
Acting Chief Executive Officer
Over 20 years of drug development experience with deep expertise in clinical pharmacology, translational medicine, and precision medicine across oncology, immunology, and antibody-drug conjugates (ADCs).
Previously held senior leadership roles at Roche, Genentech, Revolution Medicines, and Gilead, contributing to the successful development of key therapies including Tecentriq, Actemra, Giredestrant, and Trodelvy.

Jukka Muhonen
BD Executive Director
Over 25 years of international experience in business development, licensing, partnerships, and commercialization, with extensive expertise in global pharmaceutical transactions and strategic collaborations.
Previously held leadership roles at Orion Pharma and served as VP of Business Development at Orphagen Pharmaceuticals.

Wei-Han Lee, Ph.D.
Senior Director, CMC Technical Operations
Over 10 years of pharmaceutical industry experience, specializing in ADC CMC process development, site-specific conjugation technologies, and complex biologics development.
Experienced in process and analytical development from candidate selection through clinical development, with a Ph.D. in Chemistry from National Taiwan University.

David Teng-Yi Huang, Ph.D.
Senior Director, ADC Enabling Technologies
Specializes in next-generation ADC technologies, carbohydrate chemistry, and glycobiology, leading the development of GlycOBI®, ThiOBI®, EndoSymeOBI®, HYPrOBI®, and GlycOBI DUO®.
Experienced in advancing multiple clinical and preclinical ADC candidates, with a Ph.D. in Chemistry from National Tsing Hua University.
